

# HPLC Enantiomeric Separations of Pharmaceuticals Using Polar Organic Mobile Phases

J.T. Lee and William Campbell

Supelco, Div. of Sigma-Aldrich, Bellefonte, PA 16823 USA



[sigma-aldrich.com](http://sigma-aldrich.com)

T411054

# Agenda

- Background
- Benefits
- Mechanisms
- Separation Comparisons
- LC-MS Applications
- Optimization
- Screen Results
- Summary
- Conclusions

# Background

## Polar Organic Mode (POM):

- Astec CYCLOBOND™ (1989) (e.g. 95/5/0.3/0.2, CH<sub>3</sub>CN/MeOH/HOAc/TEA)
  - Acetonitrile is a dominant solvent
  - Acid/base additives are to suppress ionization
  - Samples have at least 2 H-bonds capability
- Astec CHIROBIOTIC® (neutral molecules)
- Astec P-CAP, P-CAP-DP
- Cyclofructans
- Polysaccharides (e.g. **ASTEC Cellulose DMP**)

## Polar Ionic Mode (PIM):

- Astec CHIROBIOTIC (2003) (e.g. 100/0.1/0.1, MeOH/HOAc/TEA)
  - Methanol is a dominant solvent
  - CSPs have **ionic character**
  - Acid/base additives promote ionic interactions for ionizable samples
  - **ASTEC CHIROBIOTIC V2**

# Benefits of Polar Organic Mode (POM)

## Selectivity

- Conformational changes of CSPs
- Different interaction mechanisms




## Sensitivity

- Less baseline noise in UV detection
- LC-MS compatible for biological samples


## Solubility

- Easy sample prep
- Easy scale-up

# Mechanism 1: Astec CYCLOBOND CSPs




**Reversed phase mode:** the most **hydrophobic** portion of the molecule will form an inclusion complex with the cyclodextrin cavity.



**Inclusion Complexation**


**Polar organic mode:** **CH<sub>3</sub>CN** occupies the **cavity**, so the chiral molecule lies across the surface and interacts with the upper rim of the cyclodextrin ring



**Surface Interactions**


## Mechanism 2: Astec CHIROBIOTIC CSPs

- **Macrocyclic glycopeptides** provide a multi-modal chiral surface capable of a wide variety of different interactions
- Subtle differences between them provide different, dominant retention mechanisms that lead to enantiomeric recognition
- Among these mechanisms, **ionic interactions** dominate for ionizable molecules
- A family of 6 columns
- **Macrocyclic glycopeptide CSPs** provide unique separations for polar, ionic molecules



**Vancomycin**  
(CHIROBIOTIC V2/V)

## Mechanism 3: Cellulose DMPC Derivative



Cellulose, a linear **polymer** of D-glucose linked by  $\beta(1\rightarrow4)$ -glycosidic bonds with several hundreds to over ten thousand units.

**DMPC**, 3,5-Dimethylphenyl carbamate derivatized cellulosic phase coated onto silica.


# From NP to POM: Cellulose DMP (Warfarin)

15 cm x 4.6 mm; Flow Rate: 0.5 mL/min; UV: 278 nm

50/50/0.1, EtOH/Hexane/TFA

Selectivity: 2.44


Resolution: 1.61



100/0.1, MeOH/TFA

Selectivity: 1.71


Resolution: 2.34



100/0.1, MeOH/DEA (or IPAmine)

Selectivity: 1.00


Resolution: N/A



100/0.1w%, MeOH/NH<sub>4</sub>formate

Selectivity: 1.13


Resolution: 1.40



100/0.2/0.1, MeOH/HOAc/TEA

Selectivity: 1.31



Resolution: 3.71






# Separation Comparison: Warfarin


CYCLOBOND I 2000, 25 cm x 4.6 mm  
100/0.3/0.2, CH<sub>3</sub>CN/HOAc/TEA  
Flow Rate: 1.0 mL/min, UV: 278 nm



CHIROBIOTIC V, 25 cm x 4.6 mm  
30/70, CH<sub>3</sub>CN/5 mM NH<sub>4</sub>OAc, pH 4.1  
Flow Rate: 1.0 mL/min, UV: 278 nm




Cellulose DMP, 15 cm x 4.6 mm  
100/0.2/0.1, MeOH/HOAc/TEA  
Flow Rate: 0.5 mL/min, UV: 278 nm




S-form more potent, anticoagulant

# Separation Comparison: Mianserin

Cellulose DMP, 15 cm x 4.6 mm  
10/90/0.1, IPA/Heptane/DEA  
Flow Rate: 0.5 mL/min, UV: 230 nm




Cellulose DMP, 15 cm x 4.6 mm  
100/0.1w%, MeOH/NH<sub>4</sub> formate  
Flow Rate: 0.5 mL/min, UV: 230nm




CHIROBIOTIC V2, 25 cm x 4.6 mm  
100/0.1w%, MeOH/NH<sub>4</sub> formate  
Flow Rate: 0.8 mL/min, UV: 230nm

S-active form, antidepressant




# Separation Comparison: Träger's Base


Cellulose DMP, 15 cm x 4.6 mm  
10/90/0.1, IPA/Heptane/DEA  
Flow Rate: 0.5 mL/min, UV: 230nm



Cellulose DMP, 15 cm x 4.6 mm  
100/0.1w%, MeOH/NH<sub>4</sub> formate  
Flow Rate: 0.5 mL/min, UV: 230 nm



CHIROBIOTIC V2, 25 cm x 4.6 mm  
100/0.1w%, MeOH/NH<sub>4</sub> formate  
Flow Rate: 1.0 mL/min, UV: 230 nm




# Polar Organic Mode-Cellulose DMP

100/0.1, MeOH/DEA


Flow Rate: 0.5 mL/min

UV: 230 nm


Diperodon




Homatropine




Indapamide



Mianserin



Tröger's base




# Polar Organic Mode-Cellulose DMP

100/0.1w%, MeOH/NH<sub>4</sub>Formate (LC-MS compatible)


Flow Rate: 0.5 mL/min

UV: 230 nm


Diperodon




Homatropine




Indapamide



Mianserin



Tröger's base




# Polar Organic Mode-Cellulose DMP

100% CH<sub>3</sub>CN (No additives)


Flow Rate: 0.5 mL/min

UV: 230 nm


Diperodon



Ketoconazole



Mianserin



# Cellulose DMP: NP→POM→NP→POM

Dimension: 15 cm x 4.6 mm

Flow Rate: 0.5 mL/min

Temperature: 25 ° C


UV: 254 nm,

Samples: *trans*-stilbene oxide (NP)/mianserin (POM)


NP: 90/10, Heptane/IPA

POM: 100/0.1w%, MeOH/NH<sub>4</sub>formate


NP: P:17 bar  
N eff (P1): 15896  
Selectivity: 1.92  
Resolution: 11.28




POM: P:23 bar  
N eff (P1): 13736  
Selectivity: 1.39  
Resolution: 4.19



NP: P:17 bar  
N eff (P1): 15583  
Selectivity: 1.87  
Resolution: 10.60



POM: P:23 bar  
N eff (P1): 13878  
Selectivity: 1.40  
Resolution: 4.30



# Optimization: CHIROBIOTIC (Acid/Base Ratio Effect)





## Mianserin

CHIROBIOTIC V2

25 cm x 4.6 mm

1 mL/min

UV: 230nm





# Optimization: CHIROBIOTIC (Salt Effect)





## Nicardipine

CHIROBIOTIC V2

25 cm x 4.6 mm

1 mL/min

UV: 230 nm





# Optimization: Polysaccharides (Solvent Effect)


## Ketoconazole

100/0.1w%, MeOH/NH<sub>4</sub>formate

Cellulose DMP  
15 cm x 4.6 mm  
0.5 mL/min  
UV: 230 nm



100% CH<sub>3</sub>CN



# Full Screen Results-1

10/90/0.1, IPA/Heptane/DEA

100/0.1w%, MeOH/NH<sub>4</sub> formate

Basic Pharmaceuticals	Cellulose DMP Normal Phase	Cellulose DMP Polar Organic Mode	CHIROBIOTIC V2 Polar Ionic Mode
	k <sub>f</sub> /Selectivity	k <sub>f</sub> /Selectivity	k <sub>f</sub> /Selectivity
Atropine	0.06/1.33	0.18/1.00	3.54/1.00
Bupivacaine	0.86/1.00	0.23/1.00	0.31/1.34
Citalopram	2.75/1.14	0.26/1.00	2.37/1.12
Clenbuterol	1.34/1.00	0.03/1.00	1.02/1.22
Diperodon	No elution	0.73/3.89	0.66/1.00
Disopyramide	1.65/1.07	0.11/1.02	1.08/1.14
Esmolol	3.36/1.57	0.09/1.25	1.34/1.12
Fluoxetine	1.09/1.08	0.07/1.02	2.00/1.24
Homatropine	2.40/1.62	0.08/2.04	0.13/1.00
Hydroxyzine	1.16/1.23	0.40/1.10	0.71/1.00
Indapamide	No elution	0.37/2.27	0.26/1.00
Ketamine	0.80/1.14	0.48/1.00	0.27/1.00
Ketoconazole	No elution	4.31/1.06	0.31/1.00

## Full Screen Results-2

Basic Pharmaceuticals	Cellulose DMP Normal Phase k <sub>p</sub> /Selectivity	Cellulose DMP Polar Organic Mode k <sub>p</sub> /Selectivity	CHIROBIOTIC V2 Polar Ionic Mode k <sub>p</sub> /Selectivity
Mefloquine	1.59/1.19	0.07/1.00	2.86/1.36
Methocarbamol	No elution	0.30/1/35	1.08/1.00
Methoxypheamine	0.86/1.21	0.07/1.00	1.52/1.16
Metoprolol	1.25/2.66	0.08/1.38	1.22/1.12
Mianserin	0.79/1.23	0.96/1.26	0.65/1.98
Ofloxacin	No elution	1.91/1.13	No Elution
Ondansetron	No elution	1.62/1.07	1.02/1.00
Promethazine	0.58/1.05	0.47/1.00	1.76/1.68
Propranolol	2.36/2.22	0.16/1.24	1.60/1.16
Ritalin	0.66/1.09	0.16/1.00	1.32/1.45
Thalidomide	No elution	1.20/1.00	0.47/2.97
Tolperisone	0.41/1.00	0.27/1.00	1.14/1.24
Troger's base	0.78/1.22	1.33/1.28	0.18/1.00

# Summary

Macrocyclic glycopeptides and polysaccharide CSPs can be complementary to one another using polar organic mobile phases

Suggested Sample Screen: 100/0.1w%, MeOH/NH<sub>4</sub> formate

- Astec CHIROBIOTIC V2 and T (TAG)
- Astec Cellulose DMP and “AD”-type phases
- Other CSPs
  - Different derivatives of polysaccharides
  - Immobilized polysaccharides
  - Astec P-CAP (adds 50-70% CH<sub>3</sub>CN)
  - Cyclofructans (adds 30-50% CH<sub>3</sub>CN)
  - Cinchona alkaloid ion exchange CSP (adds 30-50% CH<sub>3</sub>CN)
  - Others

# Conclusions

- Polar organic mobile phases provide additional opportunities for chiral selectivity should other types of mobile phases fail
- PIM/POM provide easy sample preparation for polar/ionizable compounds
- No memory effect (quick equilibration)
- LC-MS compatible mobile phases
- Easy scale-up for prep purification
- Straight-forward optimization steps